The new version of the National Essential Medicines List is about to enter its implementation window. The "National Essential Medicines List (2026 Edition)", jointly formulated and released by the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Center for Disease Control and Prevention, has been determined to be officially implemented nationwide from September 1st this year. The Essential Medicines List serves as a core guide for grassroots medical institutions in procurement, medical insurance reimbursement, and clinical priority drug selection. The updates and adjustments to the new version of the list will directly reshape the circulation and demand pattern of the domestic pharmaceutical market, exerting a profound impact on the product sales and channel layout of pharmaceutical enterprises. According to incomplete statistics, as of July 13th, it has been officially announced that multiple core preparations, specialty traditional Chinese patent medicines and simple preparations, and specialized chemical drugs have been successfully added to the 2026 edition of the National Essential Medicines List. The varieties included this time cover multiple clinical essential tracks such as gynecological medications, specialty traditional Chinese medicines, anti-infective drugs, chronic disease treatments, and infusion preparations, taking into account the clinical medication needs for common diseases, chronic diseases, infectious diseases, and rare diseases, and fully adapting to the diagnosis and treatment scenarios of medical institutions at all levels, especially in county and township grassroots healthcare settings. Industry analysts in the pharmaceutical sector added that the expansion and adjustment of the new version of the Essential Medicines List will accelerate the concentration of industry resources towards leading pharmaceutical companies with high-quality clinical products and comprehensive grassroots channels. Enterprises whose products are successfully included in the list are expected to continue to enjoy the benefits of the expansion of grassroots healthcare, and the terminal sales and revenue contributions of related drugs are expected to steadily increase in the future.